International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationEpidermal Growth Factor Receptor Mutation Is Associated With Longer Local Control After Definitive Chemoradiotherapy in Patients With Stage III Nonsquamous Non–Small-Cell Lung Cancer
Introduction
Lung cancer remains the leading cause of cancer-related deaths worldwide (1). Non–small-cell lung cancer (NSCLC) accounts for 80% of all cases of lung cancer, and approximately 30% of patients with NSCLC present with stage III disease 2, 3. For patients with good performance status and adequate organ function, combined chemotherapy plus radiation therapy (RT) is the standard of care 4, 5. Combined platinum-containing chemotherapy with concurrent RT has been reported to offer a median survival time of approximately 20 months 6, 7, 8, 9, 10.
The findings of driver mutations, such as mutations of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) translocation, brought paradigm shifts in the therapeutic strategy for advanced NSCLC 11, 12. The frontline treatment for mutated patients changed from platinum-based chemotherapy to the respective specific tyrosine kinase inhibitors (TKIs). The overall survival of NSCLC patients with EGFR mutations increased from 10 months to approximately 20 months with the introduction of TKIs 13, 14, 15.
A preclinical study indicated the radiosensitizing effect of gefitinib in various solid tumors 16, 17, and another study demonstrated the radiosensitive phenotype of EGFR-mutated cell lines (18). It has been retrospectively reported that the clinical response to whole-brain RT of brain metastases in patients with EGFR mutation was superior to that of wild-type EGFR (19).
In this context, it is essential to understand the baseline estimate of the EGFR-mutated population in stage III NSCLC and the biological behavior of these tumors. However, the frequency of EGFR mutations in stage III nonsquamous NSCLC patients is still unclear, because it has no clinical consequences to analyze EGFR mutational status at the time of diagnosis, considering the unsatisfactory results of previous trials that incorporated EGFR-TKI into chemoradiotherapy (CRT) 20, 21. Moreover, the impact of driver mutational status on the relapse and survival in this population is yet to be clarified.
The aim of this study was to clarify the proportion of stage III nonsquamous NSCLC patients eligible for definitive CRT who harbor EGFR mutations, and to explore the radiosensitive biology according to EGFR mutational status.
Section snippets
Patients
Between January 2001 and December 2010, a total of 528 NSCLC patients received CRT at our hospital. Under an institutional review board–approved protocol, we reviewed the medical records of all of these patients. Of these, we identified 274 patients with unresectable stage III nonsquamous NSCLC. Patients who were enrolled in clinical trials that include EGFR-TKI as study therapy (Japanese Clinical Oncology Group 0402 [21]), were enrolled in ongoing clinical trials whose results had yet to be
EGFR mutational status
Of the 274 patients intended for EGFR mutation analysis, the analysis could not be conducted in 76 because of lack of availability of specimens at our hospital (47 cases) and insufficient specimens available for analysis (29 cases) (Supplementary Fig. E1; available online at www.redjournal.org). Among the 198 patients analyzed consequently, 34 (17%) had EGFR activating mutation, and 164 (83%) had wild-type EGFR. The proportion of cases with each mutational status was as follows; exon 19
Discussion
We demostrate that the proportion of patients harboring EGFR activating mutation was 17% in stage III NSCLC patients receiving CRT. Patients with EGFR mutations showed significantly longer local control (adjusted hazard ratio 0.49; P=.043), suggesting the radiosensitive characteristic of the EGFR mutated tumors. The SPP was significantly longer in patients harboring EGFR mutations treated with EGFR-TKIs after relapse.
We found that the frequency of local relapse as the initial relapse site was
References (31)
- et al.
Locally advanced non-small cell lung cancer: The past, present, and future
J Thorac Oncol
(2008) - et al.
Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
(2013) - et al.
Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer
J Thorac Oncol
(2006) - et al.
Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer
Int J Radiat Oncol Biol Phys
(2012) - et al.
Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: A multicenter feasibility study (JCOG 0402)
Ann Oncol
(2012) - et al.
Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma
J Thorac Oncol
(2009) - et al.
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: Cancer and Leukemia Group B (CALGB) 30106, a CALGB-stratified phase II trial
J Thorac Oncol
(2010) Gamma knife stereotactic radiosurgery for synchronous versus metachronous solitary brain metastases from non-small cell lung cancer
Lung Cancer
(2003)- GLOBOCAN WHO. Cancer Fact Sheets Lung Cancer. 2012....
- et al.
Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer
J Clin Oncol
(2007)
NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007
J Clin Oncol
Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105
J Clin Oncol
Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer
Cancer Sci
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
N Engl J Med
Cited by (48)
Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: A multi-center cohort study
2023, Journal of the National Cancer CenterESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
2022, Annals of OncologyLung cancer epidermal growth factor receptor mutations and radiotherapy response: A multicentre clinical study
2021, Clinical and Translational Radiation OncologyGefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study
2021, ESMO OpenCitation Excerpt :The 2-year OS, the primary endpoint, was favorable as compared to existing survival data from a pivotal phase III trial of an EGFR-mutation-unselected, stage III population administered standard platinum-based CRT (2-year OS rate of 45%-60%)1-3 and the recent, less robust retrospective study results of ∼80% in EGFR-mutant, stage III disease with standard CRT (Supplementary Table S3, available at https://doi.org/10.1016/j.esmoop.2021.100191).9-12 We also found a 2-year PFS rate of 36.9%, which appears promising compared to EGFR-mutation-unselected population data (20%-30%)1-3 and EGFR-mutant population data (10%-25%)9-12 with standard CRT alone. Taken together, these results support that our treatment protocol should be further evaluated.
This work was supported in part by the National Cancer Center Research and Development Fund (23-A-30, 24-A-1) and by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan for Scientific Research on Innovative Areas (22131006).
Conflict of interest: T.K. reports grants from the National Cancer Center Research and Development Fund and the Ministry of Education, Culture, Sports, Science, and Technology of Japan, during the conduct of the study. T.T. reports grants from the National Cancer Center Research and Development Fund, during the conduct of the study.